[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366363-105":59,"doc-detail-366363-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","persistent-accumulation-of-therapy-induced-senescent-cells-an-obstacle-to-long-term-cancer-treatment-efficacy","Persistent accumulation of therapy-induced senescent cells - an obstacle to long-term cancer treatment efficacy","","Therapy-induced senescence (TIS) can temporarily suppress tumor growth by halting proliferation, yet the long-term persistence of therapy-induced senescent cells (TISnt) may undermine durable cancer control. This review explains how TISnt cells, through features such as the senescence-associated secretory phenotype (SASP), metabolic dysfunction, and immune evasion, create heterogeneous tumor microenvironment (TME) remodeling that promotes therapy resistance. It summarizes heterogeneous TISnt phenotypes, their multidimensional interactions in the senescent microenvironment, and current senescence-targeting strategies, proposing improved approaches for head and neck cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/persistent-accumulation-of-therapy-induced-senescent-cells-an-obstacle-to-long-term-cancer-treatment-efficacy/366363/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/persistent-accumulation-of-therapy-induced-senescent-cells-an-obstacle-to-long-term-cancer-treatment-efficacy/366363.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is therapy-induced senescence (TIS) and how is it triggered in cancer treatment?","Question",{"text":112,"@type":113},"TIS is cellular senescence induced by cancer therapeutics such as radiotherapy, chemotherapy, or targeted therapy. It arises from nonlethal DNA damage, leading to cell cycle arrest.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why can persistent therapy-induced senescent cells (TISnt) hinder long-term cancer treatment?",{"text":117,"@type":113},"Although TISnt cells can act as a barrier in the short term, their long-term persistence promotes therapy resistance, relapse, and metastasis. Their SASP-related and metabolic/immune-evading features remodel the tumor microenvironment (TME).",{"name":119,"@type":110,"acceptedAnswer":120},"What role do senescent cells in the TME play in treatment resistance, especially in head and neck cancer?",{"text":121,"@type":113},"The review notes that both malignant cells and microenvironmental cells (e.g., CAFs and TAMs) can adopt sublethal or senescent states, sustaining and intensifying the TISnt program. Examples include radiation-driven SASP signaling and senescent CAFs maintaining radioresistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366363,1790196630,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","International Journal of Oral Science [www.nature.com/ijos](www.nature.com/ijos)  \nREVIEW ARTICLE  \nOPEN  \nPersistent accumulation of therapy-induced senescent cells: an obstacle to long-term cancer treatment efﬁcacy  \nJingjing Luo 1, Tongxu Sun1, Zhenghui Liu2, Yangfan Liu1, Junjiang Liu1, Shimeng Wang1,3, Xueke Shi1 ✉ and Hongmei Zhou1 ✉  \n\n|  | In the ever-evolving landscape of cancer therapy, while cancer treatments such as chemotherapy, radiotherapy, and targeted therapy aim to eradicate malignant cells, they also inadvertently trigger cellular senescence in both cancerous and microenvironmental tissues. Therapy-induced senescence (TIS) can act as a barrier against tumor growth by halting cell proliferation in the short term, but the long-term persistence of therapy-induced senescent (TISnt) cells may pose a signiﬁcant challenge in cancer management. Their distinct characteristics, like senescence-associated secretory phenotype (SASP), metabolic dysregulation, and immune evasion, make them exhibit remarkable heterogeneity to orchestrate the tumor microenvironment (TME), resulting in therapy resistance. However, how these TISnt cells functioning differently in cancer progression, and the intricate mechanisms by which they remodel the senescence-associated immunosuppressive microenvironment present challenges for improving anticancer therapy. Therefore, this review summarizes the heterogeneous TISnt cell phenotypes contributing to an accumulated senescent state, outlines their multidimensional interactions in the senescent microenvironment, and discusses current senescence-targeting strategies. Building on the current understanding of TIS, we propose potential avenues for improving TIS-targeting methodologies in the context of head and neck cancer, a representative heterogeneous malignancy, which can |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| substantially enhance the efﬁcacy of the “one-two punch” sequential treatment approach for head and neck cancer. |  |  |\n|  | International Journal of Oral Science (2025)17:59 ; [https://doi.org/10.1038/s41368-025-00380-w](https://doi.org/10.1038/s41368-025-00380-w) |  |\n|  |  |  |\n\nINTRODUCTION  \nTherapy-induced senescence (TIS) is a form of cellular senescence triggered by cancer therapeutics, such as radiotherapy, chemotherapy or targeted therapy. This process arises from nonlethal DNA damage, leading to cell cycle arrest—a hallmark shared with replicative senescence and oncogene-induced senescence (Fig. 1) . In the short term, therapy-induced senescent (TISnt) cells act as a barrier against carcinogenesis and a booster facilitating anticancer treatments in the short term. In some cases, prosenescent antitumor therapeutics 1 are strategically crafted to impede cancer progression by activating speciﬁc prosenescent effectors,2 and inhibiting telomerase to amplify the senescent response.3 However, a growing body of evidence indicates that accumulated TISnt cells within tumor microenvironment (TME) may exert paradoxical effects, promoting therapy resistance, tumor relapse and metastasis.  \nResearch indicates that therapy-resistant cancer cells can evade treatment by exploiting the DNA damage repair response, either by entering senescence or easily escaping proliferation arrest to adopt more malignant behavior upon recovery.4,5 TIS of cancer cells also constitutes a critical mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC) . Senescent HNSCC cells that escape proliferative arrest exhibit enhanced heterogeneity and correlate with poor prognosis.6,7 Cisplatin-based chemotherapy has been experimentally conﬁrmed to induce cellular senescence in HNSCC. Therapeutically, senolytic agents may be employed to  \neliminate residual senescent tumor cells post-chemotherapy, potentially delaying disease recurrence in HNSCC patients.8,9 Meanwhile, benign stromal and i","cbCaieZpRtsJ6JVG","https://ap.wps.com/l/cbCaieZpRtsJ6JVG","pdf",3446145,21,"English","# Introduction\n## Therapy-induced senescence and cellular arrest\n## Short-term antitumor effects versus long-term persistence\n## Senescent cells in tumor microenvironment and therapy resistance\n## Persistent senescent TME and minimal residual disease","[{\"question\":\"What is therapy-induced senescence (TIS) and how is it triggered in cancer treatment?\",\"answer\":\"TIS is cellular senescence induced by cancer therapeutics such as radiotherapy, chemotherapy, or targeted therapy. It arises from nonlethal DNA damage, leading to cell cycle arrest.\"},{\"question\":\"Why can persistent therapy-induced senescent cells (TISnt) hinder long-term cancer treatment?\",\"answer\":\"Although TISnt cells can act as a barrier in the short term, their long-term persistence promotes therapy resistance, relapse, and metastasis. Their SASP-related and metabolic/immune-evading features remodel the tumor microenvironment (TME).\"},{\"question\":\"What role do senescent cells in the TME play in treatment resistance, especially in head and neck cancer?\",\"answer\":\"The review notes that both malignant cells and microenvironmental cells (e.g., CAFs and TAMs) can adopt sublethal or senescent states, sustaining and intensifying the TISnt program. Examples include radiation-driven SASP signaling and senescent CAFs maintaining radioresistance.\"}]","Persistent accumulation of therapy-induced senescent cells - an obstacle to long-term cancer treatment efficacy | PDF",1790164994,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40bac793b71848beb2d11067664e9eeb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be3238624ad7fc6e9dfa1ea3cdcc2cc4.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af139bd110ec3d256deea4fad9f970a4.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aea243e975e0452a0f88fd93cfe9a9b0.webp",980,1301]